Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Cadonilimab in HER2 Mutant Advanced Bile Duct Adenocarcinoma
NCT06383533Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2023
- Primary completion
- May 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, cadonilimab in Bile duct adenocarcinoma (CCA), sponsored by Zhejiang Cancer Hospital. Started May 2023; status: recruiting.
02
Drugs
disitamab vedotincadonilimab
03
Conditions
Bile duct adenocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06383533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383533.